| Identification | Back Directory | [Name]
Senexin A | [CAS]
1366002-50-7 | [Synonyms]
Senexin A
4-(Phenethylamino)quinazoline-6-carbonitrile
4-[(2-Phenylethyl)amino]-6-quinazolinecarbonitrile
Senexin A (This product is unavailable in the U.S.)
6-Quinazolinecarbonitrile, 4-[(2-phenylethyl)amino]- | [Molecular Formula]
C17H14N4 | [MDL Number]
MFCD23703036 | [MOL File]
1366002-50-7.mol | [Molecular Weight]
274.32 |
| Chemical Properties | Back Directory | [Boiling point ]
520.0±45.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 100 mg/mL (364.54 mM) | [form ]
Powder | [pka]
6.47±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Senexin A is a useful intermediate. | [in vivo]
Five daily treatment of Senexin A fully reverses tumor-promoting effect of chemotherapy. Senexin A shows no detectable toxicity and no significant effects on body weight, organ weights, or blood cell counts in C57BL/6 mice during the treatment. This effect of doxorubicin treatment is completely abolished, however, when doxorubicin injection is followed by administration of Senexin A. Senexin A treatment strongly improves the response of A549/MEF tumors to doxorubicin[1]. | [IC 50]
CDK19: 0.31 μM (Kd); CDK8: 0.83 μM (Kd); CDK8: 280 nM (IC50) | [storage]
Store at -20°C |
|
| Company Name: |
TCI Europe
|
| Tel: |
320-37350700 |
| Website: |
https://www.tcichemicals.com/de/de/index.html |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|